Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Xilio Therapeutics (Nasdaq: XLO) granted a non-qualified stock option to purchase 5,700 shares to a new employee effective November 1, 2025, under its 2022 Inducement Stock Incentive Plan. The exercise price is $0.7967 per share, equal to the closing price on October 31, 2025. Each option has a 10-year term.

Vesting: 25% vests on the first anniversary of employment, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service and plan/option agreement terms. The grant was made under Nasdaq Listing Rule 5635(c)(4).

News Market Reaction

-5.66% 2.2x vol

9 alerts

-5.66% News Effect

+3.5% Peak in 8 hr 26 min

-$3M Valuation Impact

$46M Market Cap

2.2x Rel. Volume

On the day this news was published, XLO declined 5.66%, reflecting a notable negative market reaction. Argus tracked a peak move of +3.5% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $46M at that time. Trading volume was elevated at 2.2x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective November 1, 2025, the company granted a non-qualified stock option to purchase 5,700 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

The stock options have an exercise price of $0.7967 per share, which is equal to the closing price of the company’s common stock on October 31, 2025. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment, and the remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to continued service with the company or any of its subsidiaries through each applicable vesting date.

The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).

Investor Contact
investors@xiliotx.com

Media Contact
Josie Butler, 1AB
josie@1abmedia.com

FAQ

What did Xilio Therapeutics (XLO) announce on November 3, 2025 about inducement grants?

Xilio announced a grant of a non-qualified stock option for 5,700 shares to a new employee effective Nov 1, 2025 under its 2022 Inducement Stock Incentive Plan.

What is the exercise price and term of the XLO inducement stock option granted Nov 1, 2025?

The exercise price is $0.7967 per share (closing price Oct 31, 2025) and each option has a 10-year term.

How does the XLO inducement option vest for the Nov 1, 2025 grant?

Vesting is 25% on the first employment anniversary, then the remaining 75% vests in 36 equal monthly installments, subject to continued service.

Under which plan and Nasdaq rule was Xilio's Nov 2025 option grant made?

The grant was made under Xilio's 2022 Inducement Stock Incentive Plan as an inducement material to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Does the XLO option grant disclosed Nov 3, 2025 change company outstanding share counts?

The announcement discloses a 5,700-share option grant but does not state current outstanding share counts or percentage dilution.

Where can investors find the terms governing the Nov 1, 2025 XLO stock option grant?

The options are subject to the 2022 Inducement Stock Incentive Plan and the specific stock option agreement covering the grant.